# MAGIC Ruxolitinib for aGVHD

> **NCT06936566** · PHASE2 · RECRUITING · sponsor: **John Levine** · enrollment: 98 (estimated)

## Conditions studied

- Acute Graft-versus-host Disease
- Allogeneic Bone Marrow Transplantation
- Adverse Effects

## Interventions

- **DRUG:** Ruxolitinib
- **DRUG:** Methylprednisolone

## Key facts

- **NCT ID:** NCT06936566
- **Lead sponsor:** John Levine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-14
- **Primary completion:** 2027-06-01
- **Final completion:** 2028-04-14
- **Target enrollment:** 98 (ESTIMATED)
- **Last updated:** 2026-03-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06936566

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06936566, "MAGIC Ruxolitinib for aGVHD". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06936566. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*